AstraZeneca Annual Report and 6 Form 20-F Information 2005 BUSINESS REVIEW INTRODUCTION CONTENTS ASTRAZENECA IN BRIEF In this section, we have applied the best Business environment 7 practice principles of the recent Operating Growing demand for healthcare 7 WE DISCOVER, DEVELOP, MANUFACTURE and Financial Review regulations and discuss AND MARKET PRESCRIPTION World markets 7 the main trends and factors underlying the PHARMACEUTICALS FOR IMPORTANT Therapy areas 7 development, performance and position AREAS OF HEALTHCARE: of AstraZeneca during 2005.
Growing challenges for industry 8 CARDIOVASCULAR, GASTROINTESTINAL, Pressure on costs 8 NEUROSCIENCE, ONCOLOGY, RESPIRATORY To that end, we provide in this Business AND INFLAMMATION, AND INFECTION Demonstrating economic benefit 8 Review an overview of AstraZenecas Productivity 8 BROAD PRODUCT RANGE, INCLUDING business environment and information about MANY WORLD LEADERS AND A NUMBER our research, development, manufacturing Drug safety 8 OF HIGH POTENTIAL GROWTH PRODUCTS: and sales and marketing activities worldwide, Competition 8 ARIMIDEX, CRESTOR, NEXIUM, SEROQUEL including our 2005 performance in these areas.
Reputation 8 AND SYMBICORT Industry regulation 8 We describe the external environment in ACTIVE IN OVER 100 COUNTRIES: which we operate, including the opportunities Strategy 9 CORPORATE OFFICE IN LONDON, UK: and challenges, the market for prescription Delivering strategy 10 R&D HEADQUARTERS IN SDERTLJE, pharmaceuticals, the competitive and SWEDEN: A MAJOR PRESENCE IN THE US: Products 10 regulatory environment, and the principal GROWING PRESENCE IN IMPORTANT Pipeline 10 risks and uncertainties.
EMERGING MARKETS Productive use of resources 11 OVER 65,000 EMPLOYEES 58% IN We describe our strategy for managing the People 11 EUROPE, 28% AMERICAS AND 14% ASIA, opportunities and challenges of our business Reputation 11 AFRICA AND AUSTRALASIA environment, the resources that we bring Measuring performance 12 to bear and how they are aligned to create AROUND 12,000 PEOPLE AT value through achievement of our strategic Reporting performance 13 11 R&D CENTRES IN 7 COUNTRIES objectives.
We also highlight the importance Therapy area review 14 14,000 PEOPLE AT 27 MANUFACTURING of leadership, effective decision-making and Cardiovascular medicines 14 SITES IN 19 COUNTRIES risk management.
Gastrointestinal medicines 18 WE SPEND $14 MILLION EACH WORKING Finally, we explain how our progress towards Neuroscience medicines 21 DAY ON DISCOVERING AND DEVELOPING achievement of our objectives is measured.
Oncology medicines 24 NEW MEDICINES Respiratory and Inflammation In the therapy area and geographic reviews medicines 27 and in the Financial Review, we report on our Infection medicines 30 financial performance during 2005 at a global level, in different geographic areas and at a Geographic review 31 product level.
We also report in detail on the Research and development 34 progress of our pipeline and developments in Development pipeline 36 relation to our marketed products such as Commercialisation and new indications, regulatory filings and clinical portfolio management 38 trial data.
Supply 39 Managing risk 40 Corporate responsibility 41 Main facilities 43 Other businesses 43 Aptium Oncology 43 Astra Tech 43 Industry regulation 43 Financial Review 45
